5-FU AND RINF-2 ALPHA IN PATIENTS WITH ADVANCED COLORECTAL CANCER

5-FU 和 RINF-2 ALPHA 在晚期结直肠癌患者中的应用

• 批准号: 3863991
• 负责人: RONALD BLUM
• 金额: --
• 依托单位: NEW YORK UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3863991
• 关键词: clinical trials; colorectal neoplasms; combination chemotherapy; drug administration rate /duration; drug adverse effect; fluorouracil; human subject; human therapy evaluation; interferons; neoplasm /cancer chemotherapy

The object of this study is to examine the response rate of the combination of 5-Fluorouracil (5-FU) administered as a loading course followed by weekly bolus therapy, in combination with rIFN-2a given subcutaneously 3 times per week; to determine the toxicity and reversibility of toxicities, duration of survival and duration of response to this treatment on colorectal carcinoma.

本研究的目的是检查组合的响应率 5-氟尿嘧啶（5-FU）作为负荷疗程给药， 每周一次推注治疗，与皮下给予的rIFN-2a联合3 次/周;为了确定毒性和毒性的可逆性， 生存期和对该治疗的反应持续时间 大肠癌